|1.||Leyssen, Pieter: 1 article (01/2015)|
|2.||Coluccia, Antonio: 1 article (01/2015)|
|3.||Laconi, Samuela: 1 article (01/2015)|
|4.||Angius, Fabrizio: 1 article (01/2015)|
|5.||Silvestri, Romano: 1 article (01/2015)|
|6.||Neyts, Johan: 1 article (01/2015)|
|7.||Pompei, Raffaello: 1 article (01/2015)|
|8.||Lacroix, Céline: 1 article (01/2015)|
|9.||Reece, P A R: 1 article (05/2004)|
|10.||Hubbard, V D: 1 article (05/2004)|
04/01/1992 - "We conducted four double-blind, controlled trials to assess the efficacy of intranasal pirodavir in experimentally induced RV infection of susceptible volunteers. "
01/01/2015 - "I-6602, an analogue of the rhinovirus inhibitor pirodavir, was previously identified as a potent inhibitor of rhinovirus infection. "
04/01/1992 - "When sprays were given six times per day for a total of 25 doses, infection, detected by either virus shedding or seroconversion, developed in 100% of the 13 placebo-treated subjects and 58% of the 12 pirodavir-treated subjects (P = 0.015). "
01/01/1992 - "Pirodavir acts at an early stage of the viral replication cycle (up to 40 min after infection) and reduces the yield of selected rhinoviruses 1,000- to 100,000-fold in a single round of replication. "
05/01/2004 - "Although no compounds for PV infections have been approved in the United States, pirodavir was one of the most promising capsid-binding compounds to show efficacy in human clinical trials for chemoprophylaxis of the common cold. "